非小细胞肺癌患者术中发现胸膜播散的预后分析

目的评估手术切除肿瘤对非小细胞肺癌(NSCLC)伴恶性胸膜播散患者预后的影响。 方法收集2011年1月至2015年12月上海市胸科医院NSCLC手术患者的临床资料,将术中意外发现胸膜播散的患者纳入研究。 结果通过术中或术后病理学检查,共有160例NSCLC患者被诊断为胸膜播散。71例(44.4%)仅行胸膜结节活检(活检组),89例(55.6%)行原发肿瘤切除术(切除组)。中位无进展生存期(PFS)和总生存期OS)分别为13个月和41个月,3、5年的无进展生存率分别为13.1%和5.7%,总生存率分别为56.0%和28.7%。切除组患者的PFS和OS均明显优于活检组(19个月vs 10个月,P＝0.000;48个月vs 33个月,P＝0.000)。切除组的3、5年无进展生存率和总生存率均高于活检组(20.8% vs 3.2%,10.8% vs 0;67.8% vs 41.0%,37.7% vs 18.2%)。接受亚肺叶切除术与肺叶切除术患者的生存差异无统计学意义(P＝0.34)。单因素和多因素分析结果显示：辅助靶向治疗、无恶性胸腔积液、T1/T2期和N0期是独立的预后因素。 结论术中诊断为NSCLC伴胸膜播散的患者可通过手术切除原发肿瘤和包括靶向治疗在内的多学科治疗获益。辅助靶向治疗、无恶性胸腔积液、低T分期、低N分期患者的预后较好。在可行的情况下,楔形切除术可能是一个合适的选择,虽然不同手术方式亚组的预后差异无统计学意义,但其创伤更小。     

Prognosis of the surgical treatment of patients with non-small cell lung cancer (NSCLC)--relation to DNA ploidy.

OBJECTIVE: The aim of this study was to evaluate prognostic importance of cell ploidy and proliferation activity in non-small cell lung cancers. Survivals were compared according to the following factors: sex, age, histology, grading, DNA ploidy, tumour size, T factor, N factor and operative procedure. METHODS: In a group of 191 patients in whom cytofluorometric examinations had been performed on archival tumour specimens, postoperative recurrences were observed. RESULTS: Postoperative recurrence was observed in 64 (64.6%) of 99 patients with aneuploid tumours and in 35 (38.0%) of 92 with diploid tumours (P<0.001). Overall survival (OS) rates for the group of 92 patients operated for diploid non-small cell lung cancer (NSCLC) at 5 and 10 years were 62 and 51.1%, whereas of other 99, operated for aneuploid tumours 33.3 and 25.9%, respectively (P<0.001). In the former group of patients disease-free survival (DFS) rates at 5 and 10 years were 58.7 and 51.4% but in the latter 29.3 and 26%, respectively (P=0.00014). Significant differences dependent on cell ploidy were also observed in OS and DFS rates of patients operated respectively for SCLC (P=0.0029; P=0.00318) and adenocarcinoma (AC; P=0.0241; P=0.02109). In general, the mean percentage of S-phase cells in non-small cell lung cancers was 14.0% (SD=13.1) in patients who survived 5 years, and 22.4% (SD=15.7) in those who had a recurrence or died (P<0.001). CONCLUSIONS: In our opinion the most important finding of our work is that determination of cell ploidy in NSCLC provides a valuable supplement to the TNM stage when evaluating late results of the surgical treatment. However, the paper demonstrates that aneuploidy, although unfavourable, is not an independent prognostic factor in the group of patients with NSCLC and in the subgroups - both with squamous cell carcinoma and adenocarcinoma. Our results show also that the percentage of S-phase cells is an independent, unfavourable prognostic factor in patients treated surgically for non-small cell lung cancer and in the subgroup with squamous cell lung carcinoma.     

老年非小细胞肺癌外科治疗80例临床效果分析

目的探讨老年非小细胞肺癌患者外科治疗临床效果。方法对我院接受治疗的80例老年非小细胞肺癌患者人院资料进行分析,医护人员根据患者治疗时间（单、双日）分为两组,每组40例患者。对照组采用西药治疗,实验组在对照组基础上进行外科手术,比较两组患者临床治疗效果等指标。结果实验组患者治疗总有效率为95％高于对照组患者（总有效率为85％）;38例实验组患者对我院治疗效果比较满意,满意度达到95％高于对照组患者;实验组患者1年生存率为45％,15例患者远期生存优于对照组患者（P〈0．05）。结论临床上,老年非小细胞肺癌患者外科治疗效果比较显著,治疗后并发症也较少,能够有效的减轻患者疼痛,值得推广使用。     

Therapeutic strategy in patients with non-small cell lung cancer associated to satellite pulmonary nodules

Objectives: In patients with non-small cell lung cancer (NSCLC) the presence of satellite metastatic nodules may be considered a contraindication to surgical treatment. The use of spiral computed tomography (CT) scan has improved the accuracy of the diagnostic assessment of pulmonary diseases, but has also led to the detection of a consistent number of indeterminate satellite lesions. Obtaining a differential diagnosis of these lesions is extremely important in defining the therapeutic strategy. The aim of the study was to assess the characteristics of satellite nodules in patients with NSCLC and to examine the diagnostic and therapeutic approach used in the presence of indeterminate satellite lesions. Methods: From November 1995 to February 2001, 29 patients (mean age 64 years) who underwent surgery for NSCLC had indeterminate satellite pulmonary lesions at the preoperative spiral CT scan. A differential diagnosis of the nodules was obtained by histological examination in 27 patients and by follow-up (62 and 64 months, respectively) in two patients. Positron emission tomography (PET) scan was selectively performed in the preoperative evaluation. Results: Thirty-two satellite nodules were analyzed in the group of 29 patients. The size of the lesions varied from 2 to 15 mm (mean 8 mm). The nodules were ipsilateral to the primary tumor in 25 patients and contralateral in four. They were benign in 22 cases and malignant in ten (metastases from NSCLC in seven patients and second primary lung cancer in three). Nodules with a size equal to or less than 5 mm were more frequently benign. Patients with stage III tumors had a higher incidence of malignant satellite nodules in comparison to earlier stages, although the data did not reach statistical significance. PET scan correctly differentiated benign and malignant satellite nodules in six patients. Conclusions: Obtaining a differential diagnosis of indeterminate pulmonary nodules associated to NSCLC is of great importance in defining the therapeutic strategy. The results of this study show that indeterminate satellite lesions may be benign or represent a second primary lung cancer, and should not therefore be considered a contraindication to surgical exploration when a preliminary differential diagnosis by other means cannot be obtained.     

78例NSCLC血清VEGF表达临床意义分析

目的检测非小细胞肺癌患者化疗前外周血血管内皮生长因子的水平,探讨其与化疗疗效、预后的关系。方法鹪联免疫吸附试验检测78例NSCLC患者化疗前血清VEGF水平,并采用x2检验、Kaplan—Meier生存曲线比较与VEGF表达相关因素及其对生存期的影响。结果在NSCLC中,血清VEGF阳性率为30．8％（24／78）。VEGF的表达与淋出结转移、远处转移、TNM分期、化疗疗效密切相关,但与年龄、性别、病理类型等无关。VEGF阳性组的生存期与阴性绀相比接近统计学意义（P=0．0741）。结论检测NSCLC患者外周血VEGF,可能有利于协助预测转移、评价化疗疗效及判断预后。     

Long term results of surgery versus continuous hyperfractionated accelerated radiotherapy (CHART) in patients aged >70 years with stage 1 non-small cell lung cancer

Background: Patients with T1N0 non-small cell lung cancer (NSCLC) are preferably treated by anatomic lobectomy. However, not all such patients are suitable for lobectomy due to their age or co-morbidity. Our aim was to determine the results obtained following lobectomy, wedge resection (WR) or continuous hyperfractionated accelerated radiotherapy (CHART) in patients aged >70 years. Patients: Two hundred and fifteen consecutive patients aged >70 years, with pathologic stage 1 NSCLC in our unit between 1991 and 2001 were studied. Of these patients, 149 had a lobectomy, 47 had a WR and 19 had CHART. Follow-up was 100% complete. Results: Analysis demonstrated the WR and CHART patients to have reduced pulmonary function (FEV₁ 59% and 52%, respectively, of predicted vs. 76%, P<0.001) when compared to the lobectomy group but there were no differences among the groups with regard to mean age and histologic tumour type. There were no operative mortality among patients after WR; however, a 2.7% 30-day operative mortality among patients undergoing lobectomy (P=0.29). Kaplan–Meier survival curves at 1 and 5 years for patients undergoing WR, lobectomy and CHART was 98% and 74% vs. 97% and 68% vs. 80% and 39%, respectively (P=0.0484). The frequency of local/regional recurrence in the WR group (19.1%) was not significantly higher than in the lobectomy group (18.4%, P=0.38) when compared to the CHART group (27%, P=0.07). Conclusion: Loco-regional recurrence and survival after WR and lobectomy in elderly patients with stage I NSCLC are comparable. Although the numbers are small, these data suggest that CHART is a reasonable treatment option for those who are not suitable candidates for surgery.     

非小细胞肺癌循环肿瘤细胞的定量检测

目的 探讨非小细胞肺癌循环肿瘤细胞(CTCs)定量检测方法 .方法 CD45免疫磁珠阴性分选组20例,CD326免疫磁珠阳性分选组25例,均为明确诊断的非小细胞肺癌患者.磁性分离富集后肺静脉与外周静脉血标本应用多参数流式细胞仪对CTCs进行定量检测.结果 阴性分选由于只能去除CD45阳性细胞,回收目的 细胞纯度低.阳性分选组中25例术中肺静脉血CTCs定量检测阳性率为64%(16/25),外周静脉血CTCs阳性率40%(10/25,P＜0.05).结论 免疫磁珠富集联合流式细胞分析检测CTCs的敏感性和特异性较高.     

培美曲塞及吉西他滨分别联合顺铂治疗初治晚期非小细胞肺癌安全性和有效性的随机对照研究

目的：探讨培美曲塞联合顺铂与吉西他滨联合顺铂治疗初治晚期非小细胞肺癌的安全性和临床有效性。方法选取我院2008年1月～2013年5月收治的64例晚期非小细胞肺癌患者进行分析研究,随机分为两组,每组32例,A 组采用培美曲塞联合顺铂进行治疗,B 组采用吉西他滨联合顺铂进行治疗。观察两组患者临床治疗效果与不良反应。结果 A 组患者治疗总有效率为28.13％,疾病控制率为78.13％;B 组患者治疗总有效率为21.87％,疾病控制率为68.75％,差异无统计学意义（P ＞0.05）。A 组患者在躯体功能、心理功能、社会功能、物质生活等各项生活质量指标上都要高于 B 组,但两组比较差异无统计学意义（P ＞0.05）。结论培美曲塞联合顺铂比吉西他滨联合顺铂治疗初治晚期非小细胞肺癌的疗效要好,且安全性高、毒副作用较小,值得临床推广应用。     

电视胸腔镜下治疗非小细胞肺癌倾向性匹配研究的系统性评价

目的：非小细胞肺癌（综合分期Ⅰ、Ⅱ期）在电视胸腔镜（VATS）下行肺叶切除术的临床疗效与传统开胸（OPEN）比较分析。方法按照 Cochrane 系统评价制作方法,收集所有倾向值匹配研究的病例对照试验,研究内容包括围手术期死亡率、复发率、术后并发症等,采用 RevMan5.0软件进行 Meta 分析。结果共纳入11篇病例对照试验,共4040例患者,Meta 分析表明：VATS 能明显降低术后肺部（P 〈0.0001,OR =0.67,95% CI：0.55~0.81）和全身（P 〈0.00001,OR =0.66,95% CI：0.57~0.76）并发症的发生率、减少肿瘤复发率（P 〈0.00001,OR =0.62,95% CI：0.53~0.71）、对总死亡率（P =0.32,OR =0.78,95% CI：0.47~1.27）与开胸术相比没有优势。结论针对非小细胞肺癌（综合分期Ⅰ、Ⅱ期）,与传统开胸术相比,VATS 能明显减少肺部及全身并发症的发生率、降低肿瘤复发率,但总死亡率相比没有优势。     

晚期非小细胞肺癌抗血管生成治疗:文献复习及病例报道

【摘要】〓肺癌是我国死亡率最高的癌症,其中非小细胞肺癌占多数。近年来研究表明,抗血管生成药物在多种实体瘤包括非小细胞肺癌中表现出了显著的疗效。阿帕替尼作用于血管内皮生长因子受体(VEGFR),临床研究证实目前其主要适应症为晚期胃癌。近年来在晚期非小细胞肺癌患者中应用阿帕替尼的临床实践日益增多,但相关报道极少。现将本院在晚期非小细胞肺癌中应用阿帕替尼的临床病例报告如下并做相关文献复习。     

单孔全胸腔镜在老年非小细胞肺癌患者中的应用

目的探讨单孔全胸腔镜在老年非小细胞肺癌（NSCLC）患者中应用的可行性与安全性。 方法收集2018年8月至2019年8月完成的209例应用单孔全胸腔镜行肺叶或者肺段手术的NSCLC老年患者（老年组）,以及同期行相同手术239例非老年患者（非老年组）的资料,并进行对比。 结果两组手术时间、术中出血量、术后住院时间、住院总费用差异无统计学意义（P>0.05）。术后两组肺部感染、肺漏气、房颤、肺栓塞等并发症情况差异无统计学意义（P>0.05）。 结论单孔全胸腔镜下肺叶或肺段手术在对老年患者与非老年患者之间围术期的疗效相当,能给老年患者带来较大的手术收益,具有较高的可行性与安全性。     

Progress in lung cancer: Non-oat cell (non-small cell lung cancer)

Lung cancer remains the greatest killing cancer in the United States with 149,000 new cases expected in 1987. The present expected mortality rate is 87 per cent. More women in the United States died of lung cancer than breast cancer in 1986. Asymptomatic, early and curable lung cancer in high risk individuals is usually found by routine chest X-ray. So-called Stage I lung cancer was reported to have a 83 per cent survival rate at three years by Martini and Beattie in 1977 and 70 per cent five year survival rate subsequently. When the more than 30,000 volunteer males were enrolled in the National Cancer Institute, national lung program for screening, 223 unsuspected lung cancers were found. 47 per cent were Stage I with a survival rate at five years of over 76 per cent. The PMI-Strang/Memorial Sloan Kettering Cancer Center study found 53 cancers in its first screen and 235 lung cancers over the next eight years of the study. Forty per cent were Stage I with a five year survival rate of 70 per cent. Sputum cytology as compared to chest X-ray was of little additional value. Studies (Martini) of N1 lung cancer was found to have a 49 per cent survival rate following resection. The N2 group of lung cancers where the mediastinal tumor was surgically removable and followed by external radiation therapy had a 27 per cent survival rate at five years. Those tumors with solitary brain metastases where the solitary brain metastasis could be resected and the primary tumor controlled, gave a 27 per cent survival rate at six years. The group of advanced N2 disease where the mediastinum could not be completely cleared were a serious group of cancers. A study of 100 patients treated from 1977 to 1980 with surgery plus internal radiotherapy followed by external radiotherapy had an overall 22 per cent survival rate for four to eight years with most of the deaths occurring because of metastases outside the chest. More recently chemotherapy has been used pre-operatively for those individuals with advanced lung cancer in the chest then followed by a combination of surgery, internal radiotherapy, external radiotherapy and more chemotherapy, if chemotherapy sensitive. This is the so-called multidisciplinary approach. In our present early studies it seems that those so treated who are chemotherapy sensitive have a 44 per cent, two year survival rate in a group of patients considered to have extremely poor prognosis. Director Kriser Lung Cancer Center, Chief Thoracic Surgery, Director Clinical Cancer Programs, Beth Israel Medical Center Chief Medical Officer Emeritus, Attending Surgeon, Member of Board of Overseers, Memorial-Sloan-Kettering Cancer Center This report is the gist of a paper read by E.J.B. at the 87th Annual Congress of the Japanese Surgical Society, Tokyo, Japan, 1987.     

Importance of tumour volume and histology in trimodality treatment of patients with Stage IIIA non-small cell lung cancer—results from a retrospective analysis

Open in a separate window OBJECTIVESChemoradiotherapy (CRT) has been the backbone of guideline-recommended treatment for Stage IIIA non-small cell lung cancer (NSCLC). However, in selected operable patients with a resectable tumour, good results have been achieved with trimodality treatment (TT). The objective of this bi-institutional analysis of outcomes in patients treated for Stage IIIA NSCLC was to identify particular factors supporting the role of surgery after CRT.METHODSIn a 2-centre retrospective cohort study, patients with Stage III NSCLC (seventh edition TNM) were identified and those patients with Stage IIIA who were treated with CRT or TT between January 2007 and December 2013 were selected. Patient characteristics as well as tumour parameters were evaluated in relation to outcome and whether or not these variables were predictive for the influence of treatment (TT or CRT) on outcome [overall survival (OS) or progression-free survival (PFS)]. Estimation of treatment effect on PFS and OS was performed using propensity-weighted cox regression analysis based on inverse probability weighting.RESULTSFrom a database of 725 Stage III NSCLC patients, 257 Stage IIIA NSCLC patients, treated with curative intent, were analysed; 186 (72%) with cIIIA-N2 and 71 (28%) with cT3N1/cT4N0 disease. One hundred and ninety-six (76.3%) patients were treated by CRT alone (high-dose radiation with daily low-dose cisplatin) and 61 (23.7%) by TT. The unweighted data showed that TT resulted in better PFS and OS. After weighting for factors predictive of treatment assignment, patients with a large gross tumour volume (>120 cc) had better PFS when treated with TT, and patients with an adenocarcinoma treated with TT had better OS, regardless of tumour volume.CONCLUSIONSPatients with Stage IIIA NSCLC and large tumour volume, as well as patients with adenocarcinoma, who were selected for TT, had favourable outcome compared to patients receiving CRT. This information can be used to assist multidisciplinary team decision-making and for stratifying patients in studies comparing TT and definitive CRT.     

Results of surgical treatment of T4 non-small cell lung cancer

Objective: Because of location and invasion of surrounding structures, the role of surgical treatment for T4 tumors remains unclear. Extended resections carry a high mortality and should be restricted for selected patients. This study clarifies the selection process in non-small cell T4 tumors with invasion of the mediastinum, recurrent nerve, heart, great vessels, trachea, esophagus, vertebral body, and carina, or with malignant pleural effusion. Methods: From 1977 through 1993, 89 patients underwent resection for primary non-small cell T4 carcinomas. Resection was regarded as complete in 34 patients (38.2%) and incomplete in 55 patients (61.8%). Actuarial survival time was calculated and risk factors for late death were identified. Results: Overall hospital mortality was 19.1% (n=17). Mean 5-year survival was 23.6% for all hospital survivors, 46.2% for patients with complete resection and 10.9% for patients with incomplete resection (P=0.0009). In patients with complete resection, mean 5-year survival for patients with invasion of great vessels was 35.7%, whereas mean 5-year survival for invasion of other structures was 58.3% (P=0.05). Age, mediastinal lymph node involvement, type of operative procedure, and postoperative radiotherapy did not significantly influence survival. Conclusion: In certain T4 tumors complete resection is possible, resulting in good mean 5-year survival especially for tumors with invasion of the trachea or carina. High hospital mortality makes careful patient selection imperative.     

Analysis of the immunological microenvironment at the tumor site in patients with non-small cell lung cancer

Background and aims Inactivation of tumor-infiltrating lymphocytes by immunomodulating cytokines shed by tumor cells into the tumor local microenvironment might be a potential escape strategy of various tumors from immune-immediate killing. Here, we provide an analysis of the cytokine profile at the tumor site in patients with non-small cell lung cancer (NSCLC).Patients and methods Using in situ hybridization (ISH), we determined the mRNA expression in lymphocytes and tumor cells for IL-2, INF-, IL-12 (p40), IL-18, IL-4, IL-10, TGF-1, IL-1, IL-3, IL-8, granulocyte-macrophage colony-stimulating factor (GM-CSF), TNF-, and TGF- in five fresh pleural effusion samples and 18 tumor tissue samples of patients with NSCLC.Results In pleural effusion as well as in tumor tissue of NSCLC patients, the mRNA expression of IL-4, IL-10, TGF-, and TGF-1 was significantly higher than that of IL-2, IL-12, IL-18 and INF-. In contrast, the analysis of tuberculosis pleural effusion samples revealed lower mRNA levels for all cytokines and did not show any significant difference among them.Conclusion The predominant mRNA expression of type II and immunosuppressive cytokines in pleural effusion and tumor tissue of NSCLC patients mirrors an immunosuppressive state in the immunological microenvironment. The present study may, therefore, help to elucidate mechanisms of tumor escape and contribute to the development of an effective immunomodulatory treatment of NSCLC.     

Results of induction chemotherapy followed by surgical resection in patients with stage IIIA (N2) non-small cell lung cancer: the importance of the nodal down-staging after chemotherapy

Objective: Chemotherapy of stage IIIA non-small cell lung cancer (NSCLC) using second generation, cisplatin-based combinations has shown to improve the results; however, the distant relapses remain the major problem. Encouraging results in the treatment of stage IV NSCLC with newer agents (gemcitabine, placlitaxel) has encouraged us to use them in stage III. The aim of this study was to assess feasibility and efficacy of induction chemotherapy with cisplatin and gemcitabine followed by surgery for patients with stage IIIA (N2) NSCLC. Methods: From February 1996 to December 1999, 36 consecutive patients with mediastinoscopically staged N2 NSCLC received three cycles of cisplatin (80 mg/m², day 2) and gemcitabine (1200 mg/m², day 1+8) followed by surgery in responding patients. Patients with stable disease or even local progression received radiotherapy. All patients had clinical N2 disease (mediastinal lymph nodes metastasis) observed on CT scan. Results: No major complications of the chemotherapy occurred. Twenty-five patients (70%) had a clinical partial response and were surgically explored, with 18 complete resections (70%). There were no in-hospital deaths, although four (16%) major complications: bronchopleural fistula (two), respiratory insufficiency (one), oesophagospleural fistula (one). In the total group of 36 patients, 3-year survival was 20%. So far, no patient without surgery has survived longer then 27 months; median survival was 8 months. In the group of the 25 patients who underwent surgery 3-year survival was 30%, with a median survival of 21 months. The difference is significant (P=0.0027). In the surgical group, the survival of patients with down staged disease (56%) was greater than that of patients with persistent N2 disease (44%) after chemotherapy (3-year survival of 59 and 0%, respectively; P=0.0013). Conclusion: induction chemotherapy with cisplatin and gemcitabine resulted in major tumour regression in a large percentage of patients with clinical N2 disease. In responding patients both the complete respectability rate and survival were higher when compared to historical controls. Survival was significantly better in patients down-staged to a mediastinal negative disease.     

Prognostic value of visceral pleura invasion in non-small cell lung cancer

Objectives: The purpose of this study was to clarify the prognostic significance of visceral pleura invasion in T2 non-small cell lung cancer (NSCLC). Materials and methods: Between 1990 and 2001, 439 consecutive patients with T2 NSCLC underwent curative surgical resection. The subjects included 234 patients with stage IB, 95 with stage IIB, and 110 with stage IIIA and B disease. The patients were divided into two groups according to the existence of visceral pleura invasion (group I without, group II with). Both groups were compared with regard to tumor size, histology, associated mediastinal lymph node involvement, and survival rates. Results: Visceral pleura invasion (group II) was identified in 114 patients (26%), and was present in 22% of patients with NSCLC with a tumor size of 3 cm or less and in 27% of those with a tumor larger than 3 cm (P=0.37). Visceral pleura invasion was associated with a higher frequency of mediastinal lymph node involvement (group I=22%, group II=34%, P=0.009). Five- and 10-year survival rates were 50 and 45% in group I, and 36 and 22% in group II (P=0.0006). In stage IB, visceral pleura invasion was identified in 53 patients (23%), and 5- and 10-year survival rates were 63 and 60% in the visceral pleura non-invasion group, and 44 and 28% in visceral pleura invasion group (P=0.0018). By multivariate Cox model analysis, age at intervention (relative RISK=1.03, P=0.0017), N status (relative RISK=1.53, P<0.0001), tumor size (relative RISK=1.83, P=0.0452) and visceral pleura invasion (relative RISK=1.42, P=0.0291) were independent predictors of poor prognosis. Conclusions: We were able to demonstrate that visceral pleura invasion was a factor of poor prognosis in T2 NSCLC. It was found to correlate with more extensive mediastinal lymph node involvement and a decreased survival rates. Therefore, the patients with visceral pleura invasion should be closely followed up especially.     

2022年V1版《NCCN非小细胞肺癌临床实践指南》更新解读

目前美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)已更新发布2022年V1版《NCCN非小细胞肺癌临床实践指南》(以下简称为《指南》)的最新内容。该指南以高质量的临床证据和最新的研究进展为基础制定非小细胞肺癌诊治标准,受到了全球临床医师的广泛认可和肯定。相比于2021年V7版《指南》有了较多的更新、修订,主要集中在靶向治疗和分子学检测方面。本文将对新版《指南》更新内容进行逐一解读。